Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

891 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD, Augé C, Morris C, Kentner S, Mulgrew K, McGlinchey K, Hair J, Hanabuchi S, Du Q, Damschroder M, Feng H, Eck S, Buss N, de Haan L, Pierce AJ, Park H, Sylwester A, Axthelm MK, Picker L, Morris NP, Weinberg A, Hammond SA. Oberst MD, et al. Among authors: de haan l. Mol Cancer Ther. 2018 May;17(5):1024-1038. doi: 10.1158/1535-7163.MCT-17-0200. Epub 2018 Mar 15. Mol Cancer Ther. 2018. PMID: 29545330 Free PMC article.
MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential.
Tigue NJ, Bamber L, Andrews J, Ireland S, Hair J, Carter E, Sridharan S, Jovanović J, Rees DG, Springall JS, Solier E, Li YM, Chodorge M, Perez-Martinez D, Higazi DR, Oberst M, Kennedy M, Black CM, Yan L, Schwickart M, Maguire S, Cann JA, de Haan L, Young LL, Vaughan T, Wilkinson RW, Stewart R. Tigue NJ, et al. Among authors: de haan l. Oncoimmunology. 2017 Feb 3;6(3):e1280645. doi: 10.1080/2162402X.2017.1280645. eCollection 2017. Oncoimmunology. 2017. PMID: 28405505 Free PMC article.
Monoclonal antibody therapeutics: history and future.
Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Buss NA, et al. Among authors: de haan l. Curr Opin Pharmacol. 2012 Oct;12(5):615-22. doi: 10.1016/j.coph.2012.08.001. Epub 2012 Aug 21. Curr Opin Pharmacol. 2012. PMID: 22920732 Review.
Use of human splenocytes in an innovative humanised mouse model for prediction of immunotherapy-induced cytokine release syndrome.
Matas-Céspedes A, Brown L, Mahbubani KT, Bareham B, Higgins J, Curran M, de Haan L, Lapointe JM, Stebbings R, Saeb-Parsy K. Matas-Céspedes A, et al. Among authors: de haan l. Clin Transl Immunology. 2020 Nov 4;9(11):e1202. doi: 10.1002/cti2.1202. eCollection 2020. Clin Transl Immunology. 2020. PMID: 33173582 Free PMC article.
The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates.
Chapman KL, Andrews L, Bajramovic JJ, Baldrick P, Black LE, Bowman CJ, Buckley LA, Coney LA, Couch J, Maggie Dempster A, de Haan L, Jones K, Pullen N, de Boer AS, Sims J, Ian Ragan C. Chapman KL, et al. Among authors: de haan l, de boer as. Regul Toxicol Pharmacol. 2012 Mar;62(2):347-54. doi: 10.1016/j.yrtph.2011.10.016. Epub 2011 Nov 6. Regul Toxicol Pharmacol. 2012. PMID: 22100994
New challenges and opportunities in nonclinical safety testing of biologics.
Baumann A, Flagella K, Forster R, de Haan L, Kronenberg S, Locher M, Richter WF, Theil FP, Todd M. Baumann A, et al. Among authors: de haan l. Regul Toxicol Pharmacol. 2014 Jul;69(2):226-33. doi: 10.1016/j.yrtph.2014.04.005. Epub 2014 Apr 19. Regul Toxicol Pharmacol. 2014. PMID: 24755365
Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation.
Prior H, Baldrick P, Beken S, Booler H, Bower N, Brooker P, Brown P, Burlinson B, Burns-Naas LA, Casey W, Chapman M, Clarke D, de Haan L, Doehr O, Downes N, Flaherty M, Gellatly N, Moesgaard SG, Harris J, Holbrook M, Hui J, Jones D, Jones K, Kedar H, Mahl A, Manninen A, McGuire A, Mortimer-Cassen E, Peraza M, Pugsley MK, Richard J, Roberts R, Roosen W, Rothfuss A, Schoenmakers A, Sewell F, Weaver R, Weir L, Wolfreys A, Kimber I. Prior H, et al. Among authors: de haan l. Regul Toxicol Pharmacol. 2020 Jun;113:104624. doi: 10.1016/j.yrtph.2020.104624. Epub 2020 Feb 29. Regul Toxicol Pharmacol. 2020. PMID: 32126256 Free article.
Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials.
Sewell F, Chapman K, Baldrick P, Brewster D, Broadmeadow A, Brown P, Burns-Naas LA, Clarke J, Constan A, Couch J, Czupalla O, Danks A, DeGeorge J, de Haan L, Hettinger K, Hill M, Festag M, Jacobs A, Jacobson-Kram D, Kopytek S, Lorenz H, Moesgaard SG, Moore E, Pasanen M, Perry R, Ragan I, Robinson S, Schmitt PM, Short B, Lima BS, Smith D, Sparrow S, van Bekkum Y, Jones D. Sewell F, et al. Among authors: de haan l. Regul Toxicol Pharmacol. 2014 Oct;70(1):413-29. doi: 10.1016/j.yrtph.2014.07.018. Epub 2014 Jul 29. Regul Toxicol Pharmacol. 2014. PMID: 25078890 Free article.
891 results